Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aleksandra Franovic

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaCourtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.
JCO Precision Oncology|February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase InhibitorJonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaCourtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.
JCO Precision Oncology|February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase InhibitorJonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Pageof 3